Indivior Pharmaceuticals, Inc. (INDV)

NASDAQ: INDV · USD

$34.8

+0.10 (+0.3%)· Recorded snapshot

Market cap	4.1B
Revenue (ttm)	1.3B
Net income (ttm)	356M
EPS (ttm)	$2.77
Shares out	118M
P/E (trailing)	12.6x
P/E (forward)	7.9x
Volume	1,307,983
Beta	1.18

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.3B
Net income (ttm): 356M
EPS (ttm): $2.77
P/E (trailing): 12.6x
P/E (forward): 7.9x
Market cap: 4.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E7.9

P25 13.4P50 20.2P75 35.7

Trailing P/E12.6

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROIC130.9

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All INDV indicators

Market & fundamental data

Available fields

246

Groups with data

Currency

USD

Showing 246 of 246 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001625297
Company name	Indivior Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	45579U109
Earnings date	2026-10-29
Earnings time	bmo
Employees	838
Employees change	-213
Employees growth	-20.27%
Enterprise value	$4.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-07-12
Fiscal year end	December
Founded	1994
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US45579U1097
Last 10-K release date	2026-02-26
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split date	2022-10-10
Last stock split type	Reverse
Market cap	$4.1B
Market cap category	Mid-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$34.83
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	INDV
U.S. state	Virginia
Website	https://www.indivior.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.54x
Average P/E ratio (10Y)	30.12x
Earnings yield	7.95%
EV/Earnings	12.15x
EV/EBIT	7.63x
EV/EBITDA	7.51x
EV/Sales	3.25x
FCF / EV yield	-2.57%
FCF yield	-2.75%
Forward EV/Sales	3.22x
Forward P/E	7.94x
Forward P/S	3x
Industry forward P/E	13.87x
Industry P/E	173.94x
Lynch fair value	$57.27
Lynch upside	67.36%
P/E ratio	12.58x
P/S ratio	3.03x
Price/EBITDA ratio	7.01x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	42.6%
EBITDA margin	43.28%
Effective tax rate	9.64%
Gross margin	85.73%
Operating margin	42.6%
Pretax margin	29.6%
Profit margin	26.75%
Profit per employee	$424,821
Profitable quarters	8
Profitable years	2
Revenue per employee	$1.6M
ROA	26.4%
ROA (5Y)	10.88%
ROCE	155.34%
ROIC	130.86%
SBC / revenue	2.4%
Tax / revenue	2.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	227.7%
EPS growth (Q)	600%
EPS growth (QoQ)	42.03%
EPS growth 10Y	8.26%
EPS growth 5Y	24.45%
EPS growth quarters	5
EPS growth years	2
FCF growth (Q)	57.45%
Gross profit growth	13.65%
Gross profit growth (Q)	18%
Gross profit growth 3Y	11.24%
Gross profit growth 5Y	13.49%
Net income growth	229.63%
Net income growth (Q)	577.78%
Net income growth (QoQ)	37.08%
Net income growth 5Y	20.69%
Net income growth quarters	5
Net income growth years	2
OCF growth (Q)	44.94%
Operating income growth	78.86%
Operating income growth (Q)	126.76%
Operating income growth 3Y	34.12%
Operating income growth 5Y	25.93%
Revenue growth	13.47%
Revenue growth (Q)	13.58%
Revenue growth (QoQ)	8.2%
Revenue growth 10Y	2.62%
Revenue growth 3Y	9.93%
Revenue growth 5Y	12.92%
Revenue growth quarters	5
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-71M
Depreciation and amortization	$9M
EBIT	$567M
EBITDA	$576M
EPS	$2.77
FCF per share	$-0.94
Financing cash flow	$-174M
Free cash flow	$-111M
Free cash flow minus SBC	$-143M
Gross profit	$1.1B
Income taxes	$38M
Investing cash flow	$-71M
Net borrowing	$147M
Net cash flow	$-288M
Net income	$356M
Operating cash flow minus SBC	$-72M
Operating income	$567M
Revenue	$1.3B
Stock-based compensation	$32M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.63
Book value per share	$-1.76
Debt / EBITDA	0.87
Interest coverage	21
Long-term assets	$508M
Long-term liabilities	$573M
Net cash (debt)	$-287M
Net cash / market cap	-7.11%
Net debt / EBITDA	0.5
Piotroski F-Score	4
Property, plant and equipment	$183M
Shareholders' equity	$-208M
Tangible book value	$-210M
Tangible book value per share	$-1.78
Total assets	$1.2B
Total cash	$222M
Total debt	$509M
Total liabilities	$1.4B
WACC	10.06%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.99
Current assets	$725M
Current liabilities	$868M
Current ratio	0.84
Inventory turnover	1.27
Net working capital	$-356M
Quick ratio	0.59
Working capital	$-143M
Working capital turnover	-10.73

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.78%
Dividend growth years	0
Dividend payment date	2026-11-06
Dividend payment years	1
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$8.13
Shareholder yield	-0.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	77.22%
10Y return CAGR	5.89%
10Y total return	77.22%
150-day SMA	$36.55
1D price change	0.3%
1M price change	-4.02%
1M total return	-4.02%
1W price change	-1.12%
1W total return	-1.12%
1Y price change	38.74%
1Y return CAGR	38.77%
1Y total return	38.74%
20-day SMA	$34.95
200-day SMA	$35.65
3M price change	-14.11%
3M total return	-14.11%
3Y price change	68.65%
3Y return CAGR	19.03%
3Y total return	68.65%
50-day SMA	$35.31
50-day SMA vs 200-day SMA	50under200
52-week high	$42.81
52-week high date	2026-06-26
52-week low	$24.28
52-week low date	2025-10-28
5Y price change	120.39%
5Y return CAGR	17.12%
5Y total return	120.39%
6M price change	0.2%
6M total return	0.2%
All-time high	$42.81
All-time high date	2026-06-26
All-time low	$1.75
All-time low date	2019-04-10
Average true range (ATR)	$1.07
Average volume	2.5M
Beta (1Y)	0.52
Beta (2Y)	0.76
Beta (5Y)	1.18
Change from 52-week high	-18.65%
Change from 52-week low	43.43%
Change from all-time high	-19.69%
Change from all-time low	1,864.57%
Change from open	0.88%
Day's gap	-0.58%
Dollar volume	$45.6M
High price	$34.85
Low price	$33.88
Monthly RSI	59.76
Open price	$34.52
Position in 52-week range	97.42%
Premarket change	-0.78%
Premarket close	$34.72
Premarket price	$34.45
Premarket volume	6.9K
Previous close	$34.72
Price vs 150-day SMA	-5.94%
Price vs 20-day SMA	-1.63%
Price vs 200-day SMA	-3.56%
Price vs 50-day SMA	-2.64%
Relative volume	0.53
RSI	45.17
Sharpe ratio	0.96
Sharpe ratio (3Y)	0.55
Sharpe ratio (5Y)	0.74
Sortino ratio	1.86
Sortino ratio (3Y)	0.91
Sortino ratio (5Y)	1.2
Volume	1.3M
Weekly RSI	46.45
YTD price change	-4.18%
YTD total return	-4.18%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	109.5M
Float percentage	92.75%
Shares change (QoQ)	-3.88%
Shares change (YoY)	0.78%
Shares held by insiders	1.84%
Shares held by institutions	98.57%
Shares outstanding	118M
Short % of float	9.51%
Short % of shares	8.82%
Short ratio	5.2 days

Deeper analysis on INDV

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this INDV report

Is a complete INDV research report available?

No complete published report is available for Indivior Pharmaceuticals, Inc. (INDV) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Indivior Pharmaceuticals, Inc. (INDV)

Price

Financial snapshot

Fair-value bridge

Latest news · INDV

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All INDV indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on INDV

Frequently asked questions